1

LabStyle InnovationsCompany Overview – March 2016

2

Disclaimer Regarding Forward-Looking StatementsThis presentation of LabStyle Innovations Corp. (the “Company”) and statements of our management or agents related thereto contain or may

contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements which are

not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and

opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be

significant factors affecting our business, including many assumptions regarding future events. Words such as "seek," "intend," "believe,"

"plan," "estimate," "expect," "anticipate", "will", "would" and other similar expressions all denote forward-looking statements within the meaning

of the Act. For example, when the Company describes the market for digital health, the Company’s U.S. launch, and the Company’s future

plans, it is using forward-looking statements

Readers are cautioned that actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could

differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks,

uncertainties and other factors. Factors that could cause or contribute to such differences include, but are not limited to our compliance with

regulatory requirements, the impact of current and any future competition, our current and future capital requirements and our ability to satisfy

our capital needs through financing transactions or otherwise, our ability to manufacture, market and generate sales of our Dario™ diabetes

management solution, as well as other factors and risks discussed in the Company's filings (including the results of the company’s commercial

and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. We undertake no obligation to publicly update any

forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by our

management or agents have been prepared by our management in good faith on a basis believed to be reasonable. However, such estimates,

forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their

attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to our future

performance. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in

conformance with generally accepted accounting principles.

3

Company Highlights

1Rapidly Emerging Industry – Digital

Health$4.5B investment in Digital Health in 2015 (*)

2Unique Native Mobile PlatformNative mobile (iOS/Android) solution

3Proven User Acceptance &

SatisfactionAmazing testimonials

4Benefit to Patients, HCPs, and PayorsUser engagement improve therapy adherence, dataprovides improved resolution for HCPs and Payors

5Multiple regulatory clearancesCleared by 4 regulatory bodies – CE, TGA (Australia),Health Canada, FDA

6Multiple Recurring Revenue Drivers Medical device disposables, Software licensing

• We are a digital (mHealth) company commercializing proprietary lab-testing capabilities using a smart phone• Our flagship product is the Dario™ Smart Diabetes Management Solution

(*) Source: http://rockhealth.com/reports/digital-health-funding-2015-year-in-review/

4

Our Vision

Delivering innovative digital health solutionsto humans.

5

Digital Health – Growing investment

$1,500

$2,000

$4,300$4,500

2012 2013 2014 2015

$ Millions

Source: http://rockhealth.com/reports/digital-health-funding-2015-year-in-review/

6

Mobile Health effecting real change:More Mobile, More Accessible, More Connected

Willing to have video visit with physician via mobile

device

60% 21% 88% 67%

Have used a mobile device to order or refill a

prescription

Willing to share personal data with doctor to find

new treatment

Very satisfied with experience at a retail clinic

Say mobile access to medical information helps

coordinate patient care

81% 38% 58% 74%

Use email to stay connected to chronic

disease patients

Would rather provide a portion of care virtually

Say non-traditional venues improve access to care

Co

nsu

me

rs

Ph

ysic

ian

s

Source: PWC Health Research Institute – December 2015

7

A new era in health

• Personalized Treatment – right treatment to the right person at the right time

• Engaging and empowering patients for better outcomes

• LabStyle’s knowhow elegantly combines mobile tech and medical devices

Source: PWC Health Research Institute – December 2015

8

Dario Smart Diabetes Management Solution

9

Global Trends in Diabetes

387 Million

387 million people have diabetes

globally

179 Million

179 million people with diabetes are

undiagnosed

592 Million

By 2035, global diabetes is expected to rise

by 205 million people

Prevalence of Diabetes Mellitus, (Age 20-79) by region,

2010 & 2030

0

20

40

60

80

100

120

NAC MENA SEA EUR SACA WP AFR

2010

2030

Source: IDF Diabetes Atlas – Sixth Edition – 2014 update

10

The Need

Improved Clinical Outcomes

Compliance Adherence

Reduced Cost of Care

11

Dario™ – Native Mobile Diabetes Management• Sleek all-in-one Smart Glucose Monitor Meter

• Robust, real-time mobile app for end to end disease management

• 100% data capturing including: blood glucose measurements, carbs & insulin intake, physical activity.

• Analyze, list and compare all this valuable information and share it with your community, family and medical staff.

• DarioCare – cloud based platform for professionals and payers

Improve Clinical Outcome!

ConnectUnderstandTrack

12

Multiple Recurring Revenue Channels

1

Device and

Disposables

Recurring revenues from

sale of disposable strips

under subscriptions

2

Diabetes

Management

• Service fees

• Clinical programs

• Tele-care providers

3

Data Monetization

Services

• Meta analysis for Payers and HMOs

• Insurers online monitoring

• Clinical studies platform

13

Dario™ Value Proposition

Users

Care Network

Payers

Payers UsersCare Network

- Online patient

management

- Improve compliance

- Reduce healthcare

costs

- Easier monitoring

- Remote follow up &

support

- Auto-alerts

- Simple to use,

smartphone based

- Complete disease

management

- Community mentor

14

User Centric Go to Market

DARIO USERS

People with Diabetes

People with Diabetes

People with Diabetes

The Right Strategy for Success

Direct to Consumer Web Marketing anddistributor sales

Engaging plans, and care providers, telemed, and clinics

Subscription models, pharmacy, retail and Durable Medical Equipment suppliers

Disease management programs

PULL

PUSH

15

Dario™ – A Warm Welcome from Users

Dario Changing Lives 2015 - Successful Launch

16

U.S. Launch

17

Expanding Global Footprint: Building to the U.S. Launch

2015 2016

18

The Dario™ World

1All-in-OnePocket-size integrated lancing device and test strips

2Complete MonitoringGives actionable insights and alerts. Calculates

sugars, insulin, A1C, carbs and activity

3AccessibilityEasy to use web portal

4EngagementMotivates through community support

5InnovationApp/software improvements every 3 month based

on user feedback and market needs

6ReachCoverage on 100% iOS and 85% Android devices

globally

19

Why LabStyle? Why Now?

Success

Lead solution in a rapidly

emerging industry – digital

& mHealth

Personalized big data

capabilities

Successful market

penetration strategy –

implemented in the

U.S. launch

Strong company Vision

and strategic roadmap

beyond Diabetes Care

20

Capitalization1

1. As of March 13, 20162. Weighted average exercise price - $14.673. Weighted average exercise price - $7.324. Of which 1,651K expiring in 2016 with potential exercise of up to 1,307K warrants for up to $5.6M

21

Management Team

Erez Raphael Chairman & CEO

Zvi Ben DavidCFO

Dror BacherVP R&D &

Operations

Todd DurniakEVP/GM North

America

LabStyle Innovations is led by an experienced management team with

vast software, medical device and technology experience and is guided by a

world class board of directors and scientific advisory board.

22

Strong Team of Advisors

Dr. Paul Rosman Prof. Itamar Raz, MD Robert G. Faissal Erez Levy

Dr. William Polonsky, PhD Hope Warshaw, MMSc Dr. Paolo Pozzilli, MD Dr. Peter Kash